ORAL BIOLOGICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Biological drugs refer to therapeutic products derived from living organisms or contain components of living organisms. Biological drugs are widely used in the treatment of number of diseases including diabetes, plaque psoriasis, arthritis, Crohn’s disease, and ulcerative colitis.

Oral biologics products refer to the biological drugs taken from oral disease indication. Currently, majority of biological drugs are administrated by parenteral route and only guanylate cyclase-c agonist class of drug is approved oral biologics in market.

However, key players in the market are involved in development of orally administered glucagon-like peptide 1 (GLP-1) receptor agonist, recombinant enzyme, somatostatin analogue, and various hormone for different indications.

Market Dynamics

Increasing number of inorganic strategies such as collaborations, partnerships, mergers, and acquisition by key players is a major factor driving growth of the market. For instance, in February 2021, Biocon Limited announced merger with International Diabetes Federation (IDF), an insulin biosimilar company, and the merger focuses on the research and development of Biocon’s biologics segment and promote the affordable access of insulin products manufactured by Biocon to the diabetes patients globally.

Key features of the study:

• This report provides in-depth analysis of the global oral biologics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global oral biologics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, Inc., Rani Therapeutics, Entera Bio Ltd., AbbVie Inc., Enteris BioPharma, Inc., Chiasma, Inc. and Allena Pharmaceuticals, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global oral biologics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oral biologics market

Detailed Segmentation:

• Global Oral Biologics Market, By Drug Class:
  • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
  • Hormone
  • Recombinant Enzyme
  • Guanylate Cyclase-C Agonist
  • Somatostatin Analogue
  • Others
• Global Oral Biologics Market, By Disease Indication:
  • Diabetes
  • Hyperoxaluria
  • Acromegaly
  • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
  • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
• Global Oral Biologics Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Oral Biologics Market, By Region:
  • North America
    • By Drug Class
      • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
      • Hormone
      • Recombinant Enzyme
      • Guanylate Cyclase-C Agonist
      • Somatostatin Analogue
      • Others
    • By Disease Indication
      • Diabetes
      • Hyperoxaluria
      • Acromegaly
      • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
      • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
    • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • By Country
      • U.S.
      • Canada
  • Latin America
    • By Drug Class
      • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
      • Hormone
      • Recombinant Enzyme
      • Guanylate Cyclase-C Agonist
      • Somatostatin Analogue
      • Others
    • By Disease Indication
      • Diabetes
      • Hyperoxaluria
      • Acromegaly
      • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
      • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
    • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Drug Class
      • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
      • Hormone
      • Recombinant Enzyme
      • Guanylate Cyclase-C Agonist
      • Somatostatin Analogue
      • Others
    • By Disease Indication
      • Diabetes
      • Hyperoxaluria
      • Acromegaly
      • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
      • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
    • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Drug Class
      • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
      • Hormone
      • Recombinant Enzyme
      • Guanylate Cyclase-C Agonist
      • Somatostatin Analogue
      • Others
    • By Disease Indication
      • Diabetes
      • Hyperoxaluria
      • Acromegaly
      • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
      • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
    • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Drug Class
      • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
      • Hormone
      • Recombinant Enzyme
      • Guanylate Cyclase-C Agonist
      • Somatostatin Analogue
      • Others
    • By Disease Indication
      • Diabetes
      • Hyperoxaluria
      • Acromegaly
      • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
      • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
    • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • By Country
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Drug Class
      • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
      • Hormone
      • Recombinant Enzyme
      • Guanylate Cyclase-C Agonist
      • Somatostatin Analogue
      • Others
    • By Disease Indication
      • Diabetes
      • Hyperoxaluria
      • Acromegaly
      • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
      • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
    • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • By Country
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • Novo Nordisk A/S *
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Biocon Limited
  • Oramed Pharmaceuticals, Inc.
  • Rani Therapeutics
  • Entera Bio Ltd.
  • AbbVie Inc.
  • Enteris BioPharma, Inc.
  • Chiasma, Inc.
  • Allena Pharmaceuticals, Inc.

“*” marked represents similar segmentation in other categories in the respective section.